OrsoBio to Unveil Liver-Targeted TLC-6740 Data at ADA’s 84th Scientific Sessions

OrsoBio, Inc., a clinical-stage biopharmaceutical company focused on treatments for obesity and associated disorders, has unveiled new data for its liver-targeted mitochondrial protonophore, TLC-6740, at the 84th Scientific Sessions of the American Diabetes Association in Orlando, Fla.

The company will present three abstracts highlighting the safety and initial efficacy of TLC-6740 in healthy humans, along with preclinical data demonstrating weight loss through enhanced energy expenditure and improved glycemic control in mouse models. These studies include monotherapy and combinations with the selective ACC2 inhibitor, TLC-3595, and a GLP-1 receptor agonist.

“Our Phase 1 data illustrate the potential of TLC-6740 to safely increase energy expenditure, offer metabolic benefits, and promote weight loss in people with obesity,” said Dr. Rob Myers, Chief Medical Officer of OrsoBio. “With these compelling clinical and preclinical findings, we are eager to advance TLC-6740 in treating obesity and its related conditions, including in combination with GLP-1 receptor agonists.”

TLC-6740 targets liver function, a pivotal organ in whole-body energy metabolism, and has demonstrated significant weight loss in rodents by enhancing energy expenditure and fat oxidation. Phase 1 data confirm TLC-6740’s safety in humans and show clinically relevant increases in energy expenditure, fat utilization, and improvements in metabolic markers like LDL cholesterol and insulin resistance.

Dr. Gerald Shulman, scientific advisor to OrsoBio, emphasized the potential of TLC-6740 to address obesity-related complications by enhancing energy expenditure and directly targeting insulin resistance.

The presentations at ADA include:

  • Abstract #1186-LB: Safety, PK, and preliminary efficacy of TLC-6740 in Phase 1 trials, demonstrating dose-dependent increases in energy expenditure and improvements in metabolic markers.
  • Abstract #899-P: Combinations of TLC-6740 and TLC-3595 show additive benefits with semaglutide in improving glycemic control in diabetic mice.
  • Abstract #1637-P: TLC-6740 enhances energy expenditure and lipid utilization in obese mice, supporting its development for obesity treatment.

These findings underscore TLC-6740’s potential to advance obesity therapy and enhance metabolic health, positioning it as a promising candidate in the biopharmaceutical landscape.

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter